gdc
PSSGuide_2021
Gastric CancerEsophageal Cancer

Drugs for Gastric Cancer/Gastroesophageal Junction Cancer

Find financial assistance programs available for gastric cancer drugs.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used alone, or in combination with paclitaxel, for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that progressed after chemotherapy.

Lilly Oncology offers 2 financial assistance programs for patients using Cyramza:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $64,400 for 1 person; $87,100 for 2 people; $109,800 for 3 people; $132,500 for 4 people; $155,200 for 5 people; and $177,900 for 6 people, this program provides Cyramza at no cost.

Enhertu (fam-trastuzumab) Injection

Drug company: Daiichi Sankyo/AstraZeneca
833-364-3788

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a previous trastuzumab-based regimen.

Daiichi Sankyo and AstraZeneca offer 2 financial assistance programs for patients using Enhertu:

Enhertu Patient Savings Program

Eligible patients who have commercial insurance may pay as little as $0 per Enhertu prescription with a maximum benefit of up to $26,000 per year to help with out-of-pocket costs. There are no income requirements to participate in this program.

Enhertu Patient Assistance Program

Patients who are uninsured, underinsured, or who have Medicare, and who meet the income eligibility requirements, may receive Enhertu for free. Medicare beneficiaries must not be eligible for or enrolled in Low Income Subsidy for Medicare Part D, and must have spent at least 3% of their annual household income on prescription medicines in the current year.

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Herceptin is a HER2 receptor antagonist used for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Genentech Oncology offers 2 financial assistance programs for patients using Herceptin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Herceptin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Herceptin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Herceptin is also provided free for patients who are unable to afford their out-ofpocket costs and cannot find other financial assistance.

Kanjinti (trastuzumab-anns)

Drug company: Amgen
888-427-7478

Kanjinti, a biosimilar to Herceptin, is a HER2/neu receptor antagonist used for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Kanjinti:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Kanjinti and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Kanjinti for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with recurrent, locally advanced, or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1, as determined by an FDA-approved test, and is progressing during or after 2 or more lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and when appropriate, HER2-targeted therapy. Keytruda is also used for the first-line treatment, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for a couple, and $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lonsurf (trifluridine + tipiracil) Tablets

Drug company: Taiho
844-824-4648

Lonsurf is a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor that is used for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in patients who received at least 2 previous lines of chemotherapy that included a fluoropyrimidine, a platinum, and either a taxane or irinotecan, and if appropriate, therapy that targets the HER2/neu gene.

Taiho Oncology offers 2 financial assistance programs for patients who have been prescribed Lonsurf:

Taiho Oncology Patient Support Co-pay Card

Patients with private insurance may be eligible to receive a copay card to help them pay an out-of-pocket cost of $0 for Lonsurf.

Taiho Oncology Patient Support Program

This program may provide Lonsurf for free to patients who have no insurance or insufficient prescription coverage and insufficient financial resources.

Ogivri (trastuzumab-dkst) Injection

Drug company: Mylan
833-695-2623

Ogivri, a biosimilar to Herceptin, is a HER2/neu receptor antagonist used for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Mylan offers 2 financial assistance programs for patients who have been prescribed Ogivri:

Mylan Advocate Co-Pay Assistance Program

This program pays the full out-of-pocket cost of Ogivri for eligible patients who have private insurance.

Mylan Advocate Patient Assistance

Uninsured patients who cannot afford the cost of Ogivri may be eligible to receive Ogivri for free. Eligibility requirements include US residency, income limits, and other factors.

Ontruzant (trastuzumab-dttb) for Injection

Drug company: Organon
844-326-2986

Ontruzant, a biosimilar to Herceptin, is used, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric cancer or metastatic gastroesophageal junction adenocarcinoma who have not received previous treatment for metastatic disease.

Organon Access Program offers 2 financial assistance programs for patients using Ontruzant:

Organon Co-Pay Assistance Program

Eligible patients who have private insurance will pay the first $5 of their copay per infusion of Ontruzant, with a maximum program benefit of $25,000 per year.

Organon Patient Assistance Program

Eligible patients who are uninsured or underinsured, or insured and having trouble paying for their medication, may receive Ontruzant at no cost through this program. You may qualify for this program if you have a household income of $64,000 or less for individuals, $87,100 or less for couples, or $132,500 or less for a family of 4.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment, in combination with fluoropyrimidine- and platinum-containing chemotherapy, of patients with advanced or metastatic gastric cancer or gastroesophageal junction cancer.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients who have been prescribed Opdivo:

BMS Oncology Co-pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who do not have public or private insurance that helps pay for Opdivo, may be eligible for help paying for Opdivo if they are receiving treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Trazimera (trastuzumab-qyyp)

Drug company: Pfizer
877-744-5675

Trazimera, a biosimilar to Herceptin, is a HER2/neu receptor antagonist used for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with chemotherapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Trazimera:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients who have private insurance so that their monthly copay for Trazimera is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Trazimera for free or at a savings. Eligible patients with government insurance may also receive Trazimera for free if they cannot find independent charitable foundation support.

Table. Drugs Prescribed for Gastric/Gastroesophageal Junction Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Enhertu (fam-trastuzumab) Injection
  • Drug company
  • Daiichi Sankyo & AstraZeneca
  • Indication
  • Treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a previous trastuzumab-based regimen
  • Patient support services
  • Enhertu Patient Savings Program
    833-364-3788

    Enhertu Patient Assistance Program
    833-364-3788


    Drug name (generic name)
  • Kanjinti (trastuzumab-anns)
  • Drug company
  • Amgen
  • Indication
  • Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
  • Patient support services
  • Amgen FIRST STEP Program
    888-427-7478

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1 and is progressing during or after 2 or more lines of therapy, including fluoropyrimidine- and platinumcontaining chemotherapy, and when appropriate, HER2-targeted therapy

    First-line treatment, in combination with trastuzumab, fluoropyrimidineand platinum-containing chemotherapy, of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Lonsurf (trifluridine + tipiracil) Tablets
  • Drug company
  • Taiho
  • Indication
  • Treatment of adults with metastatic gastric or gastroesophageal junction adenocarcinoma after at least 2 lines of chemotherapy with a fluoropyrimidine, a platinum, and a taxane or irinotecan, and if appropriate, targeted therapy for HER2/neu
  • Patient support services
  • Taiho Oncology Patient Support Co-pay Card
    844-824-4648

    Taiho Oncology Patient Support Program
    844-824-4648


    Drug name (generic name)
  • Ontruzant (trastuzumab-dttb) for Injection
  • Drug company
  • Organon
  • Indication
  • Treatment, in combination with cisplatin and capecitabine or 5-fluorouracil, of patients with HER2-overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have not received previous treatment for metastatic disease
  • Patient support services
  • Organon Co-Pay Assistance Program
    844-326-2986

    Organon Patient Assistance Program
    844-326-2986



Share this:

Last modified: March 21, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests